These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 16449809)

  • 1. What is the best choice for combination therapy in the management of dyslipidemia of metabolic syndrome?
    Turhan H; Yetkin E
    Cardiology; 2006; 105(3):139-40; author reply 141. PubMed ID: 16449809
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparison of endothelial function in patients with metabolic syndrome on bezafibrate or atorvastatin therapy.
    Hanefeld C; Bulut-Streich N; Bulut D; Graf C; Mügge A; Spiecker M
    Cardiovasc Drugs Ther; 2005 Mar; 19(2):153-5. PubMed ID: 16025235
    [No Abstract]   [Full Text] [Related]  

  • 3. Endothelial function in the forearm circulation of patients with the metabolic syndrome--effect of different lipid-lowering regimens.
    Bulut D; Hanefeld C; Bulut-Streich N; Graf C; Mügge A; Spiecker M
    Cardiology; 2005; 104(4):176-80. PubMed ID: 16155389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipid effects of peroxisome proliferator-activated receptor-δ agonist GW501516 in subjects with low high-density lipoprotein cholesterol: characteristics of metabolic syndrome.
    Olson EJ; Pearce GL; Jones NP; Sprecher DL
    Arterioscler Thromb Vasc Biol; 2012 Sep; 32(9):2289-94. PubMed ID: 22814748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The effect of treatment with fenofibrate on the risk profile of patients with metabolic syndrome and mixed dyslipidemia treated on an outpatient basis].
    Rosolová H; Bláha V; Ceska R; Hamouz Z; Pelikánová T; Soska V; Soucek M; Sucharda P
    Vnitr Lek; 2007 Apr; 53(4):339-46. PubMed ID: 17578163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of niacin and omega-3 fatty acids on the apolipoproteins in overweight patients with elevated triglycerides and reduced HDL cholesterol.
    Savinova OV; Fillaus K; Harris WS; Shearer GC
    Atherosclerosis; 2015 Jun; 240(2):520-5. PubMed ID: 25932792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The surprising AIM-HIGH results are not surprising when viewed through a particle lens.
    Otvos JD
    J Clin Lipidol; 2011; 5(5):368-70. PubMed ID: 21981836
    [No Abstract]   [Full Text] [Related]  

  • 8. Effect of rosuvastatin monotherapy or in combination with fenofibrate or ω-3 fatty acids on lipoprotein subfraction profile in patients with mixed dyslipidaemia and metabolic syndrome.
    Agouridis AP; Kostapanos MS; Tsimihodimos V; Kostara C; Mikhailidis DP; Bairaktari ET; Tselepis AD; Elisaf MS
    Int J Clin Pract; 2012 Sep; 66(9):843-53. PubMed ID: 22897461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atherogenic dyslipidemia.
    Hayden MR
    J Cardiometab Syndr; 2006; 1(3):166-7. PubMed ID: 17679821
    [No Abstract]   [Full Text] [Related]  

  • 10. Managing the dyslipidemia of metabolic syndrome: beyond statin therapy.
    Jialal I; Smith G
    Metab Syndr Relat Disord; 2012 Jun; 10(3):159-60. PubMed ID: 22568574
    [No Abstract]   [Full Text] [Related]  

  • 11. Catabolism of lipoproteins and metabolic syndrome.
    Therond P
    Curr Opin Clin Nutr Metab Care; 2009 Jul; 12(4):366-71. PubMed ID: 19474714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atherogenic dyslipidemia in the cardiometabolic syndrome.
    Govindarajan G; Chowdhury N; Flaker G
    J Cardiometab Syndr; 2006; 1(2):153-5. PubMed ID: 17679818
    [No Abstract]   [Full Text] [Related]  

  • 13. Efficacy and safety of dalcetrapib in type 2 diabetes mellitus and/or metabolic syndrome patients, at high cardiovascular disease risk.
    Stalenhoef AF; Davidson MH; Robinson JG; Burgess T; Duttlinger-Maddux R; Kallend D; Goldberg AC; Bays H
    Diabetes Obes Metab; 2012 Jan; 14(1):30-9. PubMed ID: 21819519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effect of combined antihypertensive and lipid lowering therapy on the level of coronary risk and tissue insulin resistance in patients with metabolic syndrome].
    Mamedov MN; Perova NV; Kosmatova OV; Khadipash LA; Kiseleva NV; Oganov RG
    Kardiologiia; 2003; 43(3):13-9. PubMed ID: 12891253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Diabetic dyslipidaemia and the atherosclerosis].
    Márk L; Dani G
    Orv Hetil; 2016 May; 157(19):746-52. PubMed ID: 27133274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypolipidemic therapy for the metabolic syndrome.
    Cignarella A; Bellosta S; Corsini A; Bolego C
    Pharmacol Res; 2006 Jun; 53(6):492-500. PubMed ID: 16621589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [What is the future for niacin after the AIM-HIGH study?].
    Cybulska B; Kłosiewicz Latoszek L
    Kardiol Pol; 2012; 70(3):315-6. PubMed ID: 22430425
    [No Abstract]   [Full Text] [Related]  

  • 18. Cholesterol goal attainment in hypertensive patients: the impact of metabolic syndrome components.
    Rodrigues CJ; Ribeiro HF; Ribeiro AB; Zanella MT; Batista MC
    Metab Syndr Relat Disord; 2012 Jun; 10(3):195-201. PubMed ID: 22313142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Becoming more "goal-oriented" in therapy of dyslipidemias: results of the Hungarian MULTI GAP 2010].
    Reiber I; Paragh G; Márk L; Pados G
    Orv Hetil; 2011 May; 152(21):822-7. PubMed ID: 21546340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dyslipidemia in youth with diabetes: to treat or not to treat?
    Maahs DM; Wadwa RP; Bishop F; Daniels SR; Rewers M; Klingensmith GJ
    J Pediatr; 2008 Oct; 153(4):458-65. PubMed ID: 18847618
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.